Radius Health, Inc. (RDUS)

45.02
0.39 0.87
NASDAQ
Prev Close 44.63
Open 44.33
Day Low/High 44.09 / 45.93
52 Wk Low/High 24.75 / 79.90
Volume 340.96K
Exchange NASDAQ
Shares Outstanding 43.04B
Market Cap 1.95B
Div & Yield N.A. (N.A)

Latest News

'Mad Money' Lightning Round: I'm Not Turning My Back on Blackstone

'Mad Money' Lightning Round: I'm Not Turning My Back on Blackstone

Cramer says don't buy Tesaro but do buy Cirrus Logic.

Jim Cramer's 'Mad Money' Recap: Is the Bull Resting or Out the Gate?

Jim Cramer's 'Mad Money' Recap: Is the Bull Resting or Out the Gate?

Cramer says discipline is needed to start trimming positions and taking profits.

5 Best-Positioned Biotech Stocks on Brexit Volatility

5 Best-Positioned Biotech Stocks on Brexit Volatility

Biotech stocks remain pressured following the recent Brexit vote, which will make investing in these already highly volatile stocks even trickier. But there are opportunities too.

Radius Presents Analysis Results On Fracture Risk Reduction In Phase 3 ACTIVE Trial For Investigational Drug Abaloparatide-SC At The ENDO 2016 Annual Meeting

Radius Presents Analysis Results On Fracture Risk Reduction In Phase 3 ACTIVE Trial For Investigational Drug Abaloparatide-SC At The ENDO 2016 Annual Meeting

- Data demonstrate that abaloparatide-SC reduced the risk of osteoporotic fractures and increased bone mineral density across a broad group of postmenopausal women with osteoporosis regardless of baseline characteristics -

Jim Cramer's Top Takeaways: Radius Health, Seres Therapeutics

Jim Cramer's Top Takeaways: Radius Health, Seres Therapeutics

Radius Health and Seres Therapeutics have something in common, Cramer says -- both are great biotechs being dragged down by the current market.

Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter

Jim Cramer's 'Mad Money' Recap: Good Riddance to a Roller-Coaster Quarter

When it comes to the first quarter of 2016, it was the worst of times or it was the best of times, Cramer says

'Mad Money' Lightning Round: I'm a Palo Alto Networks Guy

'Mad Money' Lightning Round: I'm a Palo Alto Networks Guy

Cramer loves Bristol-Myers and he's not betting against Goldman Sachs.

Jim Cramer's 'Mad Money' Recap: Buy These Winners When the Smoke Clears

Jim Cramer's 'Mad Money' Recap: Buy These Winners When the Smoke Clears

There are many low-value stocks that never should've gotten that low in the first place, Cramer says.

Radius Health (RDUS) Stock Price Target Cut at Cantor Fitzgerald

Radius Health (RDUS) Stock Price Target Cut at Cantor Fitzgerald

Cantor Fitzgerald lowered its price target on Radius Health (RDUS) stock to reflect lower biotechnology valuations in the current market environment.

Radius Health (RDUS) Stock Falls as Jefferies Cuts to 'Hold'

Radius Health (RDUS) Stock Falls as Jefferies Cuts to 'Hold'

Radius Health (RDUS) stock is lower in pre-market trading on a ratings downgrade to 'hold' from 'buy' at Jefferies.

Analysts' Actions -- Ford, Macy's, AT&T, Walmart and More

Analysts' Actions -- Ford, Macy's, AT&T, Walmart and More

Here are Wednesday's top research calls, including downgrades for Ford and Macy's, an upgrade for Walmart and new coverage on AT&T.

Here's Why Radius Health (RDUS) Stock Skyrocketed Today

Here's Why Radius Health (RDUS) Stock Skyrocketed Today

Radius Health (RDUS) stock closed up today after Amgen (AMGN) reported data indicating that its osteoporosis drug didn't perform as well as Radius Health's.

Amgen Osteoporosis Drug Lowers Spine Fracture Risk in Key Study

Amgen Osteoporosis Drug Lowers Spine Fracture Risk in Key Study

Amgen and partner UCB intend to seek regulatory approval for the new osteoporosis drug, romosozumab, later this year.